epirubicin has been researched along with Hepatitis C, Chronic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Igarashi, Y; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Sumino, Y; Wakui, N; Watanabe, M | 1 |
Chen, SH; Chuang, WL; Hsieh, MY; Huang, CF; Lin, CI; Lin, ZY | 1 |
1 trial(s) available for epirubicin and Hepatitis C, Chronic
Article | Year |
---|---|
Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA, Viral; Epirubicin; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Leukocyte Count; Liver Neoplasms; Male; Middle Aged; Mitomycin; Odds Ratio; Risk Factors; RNA, Viral; ROC Curve; Viral Load; Virus Activation; Virus Replication | 2011 |
1 other study(ies) available for epirubicin and Hepatitis C, Chronic
Article | Year |
---|---|
Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Ethiodized Oil; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infusions, Intra-Arterial; Japan; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Male; Prognosis | 2011 |